In a mouse model, CD30 CAR-T cells carrying three kinds of CD30 lentiviral CARs exhibited efficient cytotoxic effects on PTCL xenograft tumors, indicating that CD30 CAR-T-cell immunotherapy may be promising for cancer treatment (100). This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.